It hasn't been a great 2021 so far for the CSL (ASX:CSL) share price

What's been impacting the biotech giant's shares this years?

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has remained relatively flat when compared to the beginning of the year, up less than 3%. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up almost 14% year to date.

During Wednesday's trading session, CSL shares continued to move largely sideways, sliding 0.69% to $292.28.

How is CSL comparing against the ASX 200?

On average, the ASX 200 has returned 6.50% per annum to shareholders over the last 5 years, and 5.78% per annum over its 10-year chart. The most significant gain was achieved in 2019 when the index grew 23.02%. On the other hand, the biggest fall came in 2011, when it lost 10.84%. Surprisingly, despite the pandemic-induced crash in 2020, that year did not deliver the biggest losses thanks to the ASX 200's sharp rebound.

Why is it worth looking at the 5-year and 10-year gains of the ASX 200? The reason is that, historically, CSL shares have outperformed the ASX 200 by a significant margin. Over the past 5 years, the company has delivered a 155% return. When looking at the last 10 years, the CSL share price has jumped by around 930% over the period.

What's been affecting the CSL share price lately?

CSL has been marred with plasma collection issues stemming from early 2020 when COVID-19 arrived on the world stage. Governments around the world enforced restrictions on passenger movements and closed down international borders in an effort to help curb the spiralling outbreak.

This was particularly bad news for CSL as it relies on the plasma from blood donors to make its life-saving medicines.

The company last provided an update in March advising that December 2020 plasma volumes were sitting at around 80% of December 2019 levels.

While current plasma levels are expected to eventually bounce back, no one can be certain exactly when this will occur. This uncertain environment has likely weighed on investor optimism, sending CSL shares in circles over the past 18 months.

The most recent broker note on CSL came from Macquarie yesterday. The broker cut its 12-month price target for CSL shares by 1.3% to $308.00. Based on the current CSL share price, this implies an upside of around 5% to investors.

CSL share price snapshot

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, but are up just 5.08%. The company's shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.

On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $133 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »